FDA shows what flexibility looks like 

Plus Biohaven’s verdiperstat misses again and updates from Meliora, Sarepta and more

Restoring neurotransmission may be the key to slowing fatal disease

Biotech engaging with FDA to determine path forward for rare disease program destined for spinout after Pfizer deal

Acceleron rumors, Somatrogon delay, Keytruda in HCC, verdiperstat data and more

The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets

A composite analysis showing reductions in cardiac death, stroke and heart attack in Mesoblast’s Phase III heart failure trial appears to have allayed investor concerns following the

Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year

The idea that neuroinflammation drives ALS will get its most rigorous test to date with the Healey ALS platform trial.